Velimogene Aliplasmid

Summary

Velimogene Aliplasmid (CHEMBL2108663) is a phase-3 clinical-stage gene; indicated across 1 condition including melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 1 condition

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108663
Name	Velimogene Aliplasmid
Type	Gene
Max phase	3

Also known as: Dna (plasmid vcl-1005), Velimogen aliplasmido, Velimogene aliplasmid, Velimogene aliplasmide, VELIMOGENE ALIPLASMID

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
melanoma	3	MONDO:0005105	EFO:0000756

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).